Pretax income in the first quarter of 1997 at Danish company NovoNordisk was 560 million Danish kroner ($87 million), up 1% on that achieved in the first three months of 1996. Net income was 398 million kroner, compared with 396 million kroner a year earlier, and earnings per share were 5.30 kroner, compared with 5.28 kroner in the 1996 first quarter. Analysts Mark Tracey and John Murphy of Goldman Sachs noted that profits were adversely affected by a difficult base comparison, adding that earnings were in line with expectations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze